Application 206077
- Type
- ANDA
- Sponsor
- FRESENIUS KABI USA
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | DAPTOMYCIN | DAPTOMYCIN | POWDER;INTRAVENOUS | 500MG/VIAL | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 63323-371 | Daptomycin | Daptomycin | Fresenius Kabi USA, LLC | ANDA | Current |
| 63323-371 | Daptomycin | Daptomycin | Fresenius Kabi USA, LLC | ANDA | Current |
| 63323-371 | Daptomycin | Daptomycin | Fresenius Kabi USA, LLC | ANDA | Current |
| 63323-371 | Daptomycin | Daptomycin | Fresenius Kabi USA, LLC | ANDA | Current |
| 63323-371 | Daptomycin | Daptomycin | Fresenius Kabi USA, LLC | ANDA | Current |
| 63323-371 | Daptomycin | Daptomycin | Fresenius Kabi USA, LLC | ANDA | Current |
| 63323-371 | Daptomycin | Daptomycin | Fresenius Kabi USA, LLC | ANDA | Current |
| 63323-371 | Daptomycin | Daptomycin | Fresenius Kabi USA, LLC | ANDA | Current |